Jingjie Yi

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

acs.org

pubs.acs.org

Articles

Iron regulatory proteins: players or pawns in ferroptosis and cancer?

Jun 29, 2023 | frontiersin.org | Yanqing Liu |Jingjie Yi |Bowen Tang |Yue Liu

Cameron J. Cardona and McKale R. Montgomery*Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK, United StatesCells require iron for essential functions like energy production and signaling. However, iron can also engage in free radical formation and promote cell proliferation thereby contributing to both tumor initiation and growth. Thus, the amount of iron within the body and in individual cells is tightly regulated.
Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53

Jun 27, 2023 | dx.doi.org | Ning Sun |Xiaoping Hu |Tiphaine C Martin |Jingjie Yi

With advances in chemically induced proximity technologies, heterobifunctional modalities such as proteolysis targeting chimeras (PROTACs) have been successfully advanced to clinics for treating cancer. However, pharmacologic activation of tumor-suppressor proteins for cancer treatment remains a major challenge. Here, we present a novel Acetylation Targeting Chimera (AceTAC) strategy to acetylate the p53 tumor suppressor protein.
Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1 - Cell Death & Differentiation

Jun 8, 2023 | nature.com | Bo Chu |Jian Jin |Jingjie Yi

AbstractAlthough numerous studies indicate that inhibition of USP7 suppresses tumor growth by activating p53, the precise mechanism by which USP7 contributes to tumor growth through the p53-independent manner is not well understood. p53 is frequently mutated in most triple-negative breast cancers (TNBC), characterized as the very aggressive form of breast cancers with limited treatment options and poor patient outcomes.
Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53

May 5, 2023 | pubs.acs.org | Ning Sun |Xiaoping Hu |Tiphaine C Martin |Jingjie Yi

With advances in chemically induced proximity technologies, heterobifunctional modalities such as proteolysis targeting chimeras (PROTACs) have been successfully advanced to clinics for treating cancer. However, pharmacologic activation of tumor-suppressor proteins for cancer treatment remains a major challenge. Here, we present a novel Acetylation Targeting Chimera (AceTAC) strategy to acetylate the p53 tumor suppressor protein.